Long-term safety of cyclosporine in the treatment of psoriasis

Archives of Dermatology

Volumn 132, Issue 6, 1996, Pages 623-629

  Grossman, Rachel M ^a,c   Chevret, Sylvie ^a   Abi Rached, Johnny ^a   Blanchet, Françoise ^b   Dubertret, Louis ^a  

^a Saint Louis Hospital   (France)

^b BICHAT HOSPITAL   (France)

^c JOHNSON AND JOHNSON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN;

ADULT; AGED; ARTICLE; DRUG EFFECT; DRUG SAFETY; FEMALE; GINGIVA HYPERPLASIA; HEADACHE; HUMAN; HYPERTENSION; HYPERTRICHOSIS; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; MALIGNANT TRANSFORMATION; MUSCLE CRAMP; NAUSEA; NEPHROTOXICITY; PARESTHESIA; PRIORITY JOURNAL; PSORIASIS; TREMOR; VERTIGO;

ADOLESCENT; ADULT; AGED; CYCLOSPORINE; FEMALE; HUMANS; HYPERTENSION; IMMUNOSUPPRESSIVE AGENTS; KIDNEY; MALE; MIDDLE AGED; NEOPLASMS; PSORIASIS; TIME FACTORS;

EID: 0029975192     PISSN: 0003987X     EISSN: None     Source Type: Journal    
DOI: 10.1001/archderm.132.6.623     Document Type: Article

References (37)

1. Mueller W, Hermann B. Cyclosporin A for psoriasis. N Engl J Med. 1979;301: 555.
2. Ellis CN, Gorsulowsky DC, Hamilton TA, et al. Cyclosporine improves psoriasis in a double-blind study. JAMA. 1986;256:3110-3116.
3. Marks JM. Cyclosporin A treatment in severe psoriasis. Br J Dermatol. 1986; 115:745-746.
4. Griffiths CEM, Powles AV, Leonard JN. Clearance of psoriasis with low dose cyclosporine. BMJ. 1986;293:731-732.
5. Fry L, Griffiths CEM, Powles AV, Baker BS, Valdimarsson H. Long-term cyclosporine in the management of psoriasis. Transplant Proc. 1988;20 (suppl 4):23-25.
6. Meinardi MMHM, Bos JD. Cyclosporine maintenance therapy in psoriasis. Transplant Proc. 1988;20(suppl 4):42-48.
7. Ellis CN, Fradin MS, Messana JM, et al. Cyclosporine for plaque-type psoriasis: results of a multidose, double-blind trial. N Engl J Med. 1991;324:277-284.
8. Timonen P, Friend D, Abeywickrama K, Laburte C, Von Graffenried B, Feutren G. Efficacy of low-dose cyclosporin A in psoriasis: results of dose-finding studies. Br J Dermatol. 1990;122(suppl 36):33-40.
9. Laburthe C, Grossman RM, Abi-Rached J, Abeywickrama KH, Dubertret L. Efficacy and safety of oral Sandimmune for long-term treatment of chronic plaque psoriasis. Br J Dermatol. 1994;130:366-375.
10. Mihatsch M, Wolff K. Consensus conference on cyclosporin for psoriasis. Br J Dermatol. 1992;126:621-623.
11. Feutren G, Mihatsch M, and the International Kidney Biopsy Registry of Cyclosporine in Autoimmune Diseases. Risk factors for cyclosporine-induced nephropathy in patients with autoimmune diseases. N Engl J Med. 1992;326: 1654-1660.
12. Cameron S, Davison AM, Grunfeld JP, Kerr D, Ritz E. Oxford Textbook of Clinical Nephrology. New York, NY: Oxford University Press Inc; 1992;1:24-69.
13. Cutler SJ, Ederer F. Maximum utilization of the life-tables methods in analyzing survival. J Chronic Dis. 1958;8:699-713.
14. Kaplan E, Meier P. Non parametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457-481.
15. Peto R, Peto J. Asymptomatically efficient rank invariant test procedures. J R Stat Soc. 1972;135:185-206.
16. Jessner M, Kanof NB. Lymphocytic infiltration of the skin. Arch Dermatol Syphilol. 1953;68:447-449.
17. Bagot M, Dubertret L. Lymphocytic infiltrates of the skin in association with cyclosporine therapy. J Am Acad Dermatol. 1992;26:283.
18. Lewis HM, Powles AV, Thomas E, et al. Cyclosporin A in the treatment of chronic plaque psoriasis: six years' experience. J Dermatol Treatment. 1993;4:3-7.
19. Bennett WM. Renal effects of cyclosporine. J Am Acad Dermatol. 1990;23: 1280-1287.
20. Dieterle A, Abeywickrama K, von Graffenreid B. Nephrotoxicity and hypertension in patients with autoimmune diseases treated with cyclosporin. Transplant Proc. 1988;20(suppl 4):349-355.
21. Feutren G, Abeywickrama K, Friend D, von Graffenreid B. Renal function and blood pressure in psoriatic patients treated with cyclosporin A. Br J Dermatol. 1990;122(suppl 36):57-69.
22. Fradin MS, Ellis CN, Voorhees JJ. Management of patients and side effects during cyclosporine therapy for cutaneous disorders. J Am Acad Dermatol. 1990;23:1265-1275.
23. De Rie MA, Meinardi MMHM, Bos JD. Analysis of side effects of medium- and low-dose cyclosporin maintenance therapy in psoriasis. Br J Dermatol. 1990; 123:347-353.
24. Zachariae H, Hansen HE, Kragballe K, Olsen S. Morphologic renal changes during cyclosporine treatment of psoriasis. J Am Acad Dermatol. 1992;26:415-419.
25. Feutren G, Mason J. Serum creatinine or glomerular filtration rate for monitoring cyclosporine therapy. Lancet. 1991;338:1017.
26. Silverman A, Emmett M, Menter A. Can maintenance cyclosporine be used in psoriasis without decreasing renal function? Semin Dermatol. 1992;11:302-312.
27. Tomlanovich S, Gollbetz H, Pelroth M, Stinson E, Myers BD. Limitations of creatinine in quantifying the severity of cyclosporine-induced chronic nephropathy. Am J Kidney Dis. 1986;8:332-337.
28. Gilbert SC, Emmett M, Menter A, Silverman A, Klintmalm G. Cyclosporine therapy for psoriasis: serum creatinine measurements are an unreliable predictor of decreased renal function. J Am Acad Dermatol. 1989;21:470-474.
29. Textor SC, Canzenello VJ, Taler SJ, et al. Cyclosporine-induced hypertension after transplantation. Mayo Clin Proc. 1994;69:1182-1193.
30. Curtis JJ, Luke RG, Jones D, Diethelm AG. Hypertension in cyclosporine-treated renal transplant recipients is sodium-dependent. Am J Med. 1988;85: 134-138.
31. Ferguson CJ, von Ruhland C, Shrestha B, Griffin PJ, Moore RH, Salaman JR. Enalapril and cyclosporin in renal transplant patients and rats. Transplant Proc. 1994;26:2600-2601.
32. Van den Dorpel MA, Zietse R, Ijzermans JN, Schalekamp MA, Weimar W. Effect of isradipine on cyclosporin-induced hypertension. Blood Press. 1994;1 (suppl):50-53.
33. Krupp P, Monka C. Side-effect profile of cyclosporin A in patients treated for psoriasis. Br J Dermatol. 1990;122(suppl 36):47-56.
34. Cockburn ITR, Krupp P. The risk of neoplasms in patients treated with cyclosporine A. J Autoimmun. 1989;2:723-731.
35. Penn I. Malignancy after immunosuppressive therapy. Clin Immunother. 1995; 4:207-218.
36. Alloub M, Barr B, McLaren KM, Smith IW, Bunney MH, Smart GE. Human papillomavirus infection and cervical intraepithelial neoplasia in women with renal allografts. BMJ. 1989;298:153-156.
37. Pirn D, Collins M, Banks L. Human papillomavirus type 16 E5 gene stimulates the transforming activity of the epidermal growth factor receptor. Oncogene. 1992;7:27-32.